Six Flags Shuts Down X2 Rollercoaster Amid Brain Injury Allegations
The closure follows multiple lawsuits alleging that riders suffered brain injuries on the ride, which spins seats 360 degrees.
Written by EGazette’s AI. The facts are drawn from cited sources; the analysis is the AI’s own.
Six Flags has shut down its X2 rollercoaster after facing multiple lawsuits from riders who allege they suffered brain injuries from the attraction, which features seats that spin 360 degrees during the ride.
According to the allegations, hundreds of riders have reported experiencing brain injuries linked to the ride's motion, prompting legal action against the theme park operator over the safety of the attraction.
The X2 has been known as one of the more intense rollercoasters in the Six Flags portfolio, distinguished by its spinning-seat design, which some of the lawsuits reportedly identify as a contributing factor to the alleged injuries.
The company's decision to shut down the ride suggests a response to mounting legal and safety scrutiny, though it has not been detailed publicly whether the closure is temporary pending investigation or represents a permanent retirement of the attraction.
The lawsuits and subsequent closure raise broader questions about safety oversight for high-intensity amusement park rides, an issue that could draw further attention from regulators and the amusement park industry more broadly.
Sources
- Six Flags shuts down X2 rollercoaster after hundreds allege brain injuries — BBC News — World
EGazette summarizes reporting from multiple sources; follow the links for the originals.
Comments
Loading comments…
Related articles
Six Flags permanently closes X2 rollercoaster after brain injury claims
More than 100 people say they were injured on the ride, which reached speeds of up to 76mph.
Trump, AI Industry Leaders Sign Voluntary Safety Accord
The agreement outlines internal controls and independent audits as concerns grow over artificial intelligence oversight.
Mistral CEO states U.S. AI safety debate masks competitors’ 'negligence'
A report from CNBC — Top News sets out the main available details, with claims kept attributed to their sources.
Retatrutide trial results mark new milestone for weight-loss drugs, researchers say
The experimental triple-agonist drug is the first of its kind to reach a phase 3 clinical trial, according to researchers describing the results as a high-water mark for the field.
One in Eight Cancers Worldwide Linked to Infections, WHO Agency Finds
A new IARC study estimates that 2.3 million new cancer cases in 2024 were caused by infections that could be prevented through treatment or vaccination.
Two Indian Nationals Charged With Smuggling Counterfeit Ozempic From China, DOJ Says
The Justice Department announced criminal charges against two Indian nationals accused of smuggling counterfeit versions of the weight-loss drug Ozempic from China into Florida.